Trial of Trastuzumab Deruxtecan in Previously Treated HER2

The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.

Trial Details

NCT ID
NCT06750484
Phase
PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Trastuzumab Deruxtecan
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Must be competent and able to comprehend, sign, and date an Institutional Review Board (IRB) approved ICF before performance of any study-specific …
  • Men or women ≥18 years old.
  • Pathologically documented breast cancer that is unresectable or metastatic.
  • 4.Tumor biopsies have always shown HER2-IHC 0 (\<10% membrane staining, including 0 null and 0 ultralow) in all prior biopsies and never previously…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →